Sun Pharma has announced the acquisition of Canadian commercial sales rights for LEVULAN KERASTICK (aminolevulinic acid hydrochloride), a long-established photodynamic therapy (PDT) used to treat non-hyperkeratotic actinic keratoses (AKs) of the face and scalp. The rights were acquired at no cost from Clarion Medical Technologies.
LEVULAN KERASTICK has been in use for more than two decades and has treated over four million patients worldwide. The therapy provides a precise, in-clinic treatment option with a strong safety and efficacy profile, helping prevent the progression of actinic keratoses into skin cancer.
The acquisition strengthens Sun Pharma’s dermatology portfolio in Canada, where the company has been expanding since 2021 through partnerships and offerings in biologics, acne therapeutics, and now photodynamic therapy.
With LEVULAN KERASTICK joining its portfolio, Sun Pharma Canada will ensure continued product availability and provide health care practitioners with direct access to its national representative network for education, training, and clinical information.
Photodynamic therapy continues to play an important role in managing actinic keratoses across the country. The addition of LEVULAN KERASTICK to Sun Pharma’s portfolio reinforces the company’s commitment to supporting Canadian patients and clinicians with reliable dermatology treatment options.
Also Read